RiverVest Venture Partners United States

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

Year Founded
2000
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Karen Spilizewski
VP 

Sanus Advisory Asia Singapore

Sanus Asia is a Singapore based advisory firm providing investment and transaction-related services across Asia with a focus on Healthcare and Life Sciences.

We work with investors and high potential companies to assist growth/development across Asia through capital raising and strategic/operational support.

We seek to identify high potential US/European Medtech and Digital Health companies with near-term commercialisation potential in Asia.

Will also consider earlier stage investments as a principal Angel investor if there is a strong Asian angle to the technology/business model.

Dr Ronald Ling
LinkedIn logo Managing Director 

Seroba Kernel Life Sciences Ireland

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Year Founded
2001
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Daniel O'Mahony
Partner 

Sofia Angel Fund United States

Sofia Angel Group is a group of angel investors based in Minneapolis, Minnesota. The group solely focuses on investing in women-led businesses where women are the founders, or women are on the senior management team. Sofia Angel Group does not have a specific timeframe to make an investment, however would make an allocation by the end of 2013 if a compelling opportunity is identified. The group typically invests around $100,000 per company, however has the ability to invest up to $3 million through co-investments from the group’s members.

Barbara Nelsen

Sound Affects

Sound Affects is a philanthropic organization based in Westport CT. Sound Affects is a nonprofit crowdfunding platform that will provide non-dilutive research grants to for-profit life science companies developing products in the oncology sector. Sound Affects? grant sizes are variable depending on project needs with current projects seeking to raise between $5 and $5, the amount of funding sought should be sufficient to reach the next product development milestone. Sound Affects is potentially open to funding about 4 further projects and is best placed to work with entrepreneurs based in the Northeast/Mid-Atlantic region of the USA but is also open to proposals from outside this region. In addition to direct crowdfunding Sound Affects will in the future provide additional resources via a matching fund.
Mona Jhaveri
Executive Director 

Symbient Product Development United States

Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing

Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.

 

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.

 

Our Portfolio Includes:

  • Diagnostics / Molecular Diagnostics
  • Sample collection / preparation
  • Life Sciences / Microfluidics
  • OTC Consumer products
  • Respiratory
  • Surgical devices and clinical tools
  • Drug Delivery

 

Year Founded
2004
Unique Capabilities

Our Services Include:

  • Concept Development
  • Development Engineering
  • Design-for-Manufacturing
  • Industrial Design
  • Project Rescue
  • Design Control per IOS 13485
  • Finite Element Analysis (FEA)
  • Design Verification Testing
  • Test Method Development
  • Transfer to Manufacturing

 

Our In-House Capabilities and Expertise Include:

  • Stereolithography (SLA) Prototyping
  • CNC Machining / Fabrication
  • Prototype Mold Fabrication
  • Prototype Injection Molding of Devices for Testing, Trials and Studies
  • Liquid Injection Molded (LIM) Silicone Prototype Molding
  • Product Reliability Testing
  • Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
  • Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
  • Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.
Lisa Coyne
Business Development Manager 
Luke Helm
Director of Business Development 

Syncona Partners United Kingdom

Syncona Partners, founded in 2012, is an evergreen investment firm based in London, UK. The firm is an independent subsidiary of the Wellcome Trust who invested the initial £200m capitalization. The firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients, and to hold an ownership position to create value for the Wellcome Trust. The firm is actively screening new investment opportunities.

Year Founded
2012
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Chris Hollowood
Partner 

Tech Coast Angels

Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.

Websites:
www.greenwingsbiomedical.com
techcoastangels.com

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Richard Koffler
Member